Pharma BD Deal Intelligence
Niaspan rode a marketing-driven prescription boom to ~$1.1B in US sales, then the clinical rationale collapsed (AIM-HIGH, 2011) and the FDA ultimately pulled the niacin-combo products from the market in 2016 — a franchise built on a thesis that didn't survive its own trial data.
Full analysis, sources & comparables →Abbott expects the transaction to be $0.02 to $0.03 dilutive to ongoing earnings per share in 2007, neutral to accretive in 2008 and building to significant…
Abbott's $78-per-share cash offer represented a premium of nearly 56 percent over Kos's Friday close of $50.09; Kos's main products Niaspan and Advicor are…
Kos board recommended Abbott's $78/share tender offer; financial advisors confirmed fairness based on Niaspan franchise economics, Simcor pipeline value and…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Cardiovascular/lipid management; Niaspan, Advicor; $78/share
Niaspan rode a marketing-driven prescription boom to ~$1.1B in US sales, then the clinical rationale collapsed (AIM-HIGH, 2011) and the FDA ultimately pulled the niacin-combo products from the market in 2016 — a franchise built on a thesis that didn't survive its own trial data.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / Kos Pharmaceuticals Inc. (this deal) | 2006 | $3.7B | 33 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
← Browse all deals · How we score deals
More: 2006 deals · Abbott Laboratories deals